Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00514947 | Lung | IAC | negative regulation of cytoskeleton organization | 38/2061 | 163/18723 | 5.35e-06 | 2.08e-04 | 38 |
GO:00322318 | Lung | IAC | regulation of actin filament bundle assembly | 28/2061 | 105/18723 | 6.21e-06 | 2.30e-04 | 28 |
GO:00336748 | Lung | IAC | positive regulation of kinase activity | 83/2061 | 467/18723 | 6.76e-06 | 2.45e-04 | 83 |
GO:00300388 | Lung | IAC | contractile actin filament bundle assembly | 28/2061 | 106/18723 | 7.56e-06 | 2.64e-04 | 28 |
GO:00431498 | Lung | IAC | stress fiber assembly | 28/2061 | 106/18723 | 7.56e-06 | 2.64e-04 | 28 |
GO:00322323 | Lung | IAC | negative regulation of actin filament bundle assembly | 14/2061 | 35/18723 | 9.02e-06 | 3.02e-04 | 14 |
GO:00452168 | Lung | IAC | cell-cell junction organization | 43/2061 | 200/18723 | 1.21e-05 | 3.64e-04 | 43 |
GO:00514973 | Lung | IAC | negative regulation of stress fiber assembly | 13/2061 | 32/18723 | 1.54e-05 | 4.49e-04 | 13 |
GO:20001168 | Lung | IAC | regulation of cysteine-type endopeptidase activity | 48/2061 | 235/18723 | 1.65e-05 | 4.73e-04 | 48 |
GO:01100208 | Lung | IAC | regulation of actomyosin structure organization | 26/2061 | 100/18723 | 2.14e-05 | 5.98e-04 | 26 |
GO:01100538 | Lung | IAC | regulation of actin filament organization | 54/2061 | 278/18723 | 2.27e-05 | 6.28e-04 | 54 |
GO:00432977 | Lung | IAC | apical junction assembly | 22/2061 | 78/18723 | 2.31e-05 | 6.34e-04 | 22 |
GO:19029047 | Lung | IAC | negative regulation of supramolecular fiber organization | 37/2061 | 167/18723 | 2.38e-05 | 6.50e-04 | 37 |
GO:00525478 | Lung | IAC | regulation of peptidase activity | 80/2061 | 461/18723 | 2.39e-05 | 6.50e-04 | 80 |
GO:01501054 | Lung | IAC | protein localization to cell-cell junction | 10/2061 | 21/18723 | 2.86e-05 | 7.44e-04 | 10 |
GO:00513488 | Lung | IAC | negative regulation of transferase activity | 52/2061 | 268/18723 | 3.30e-05 | 8.29e-04 | 52 |
GO:00514928 | Lung | IAC | regulation of stress fiber assembly | 24/2061 | 91/18723 | 3.40e-05 | 8.43e-04 | 24 |
GO:00432818 | Lung | IAC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 43/2061 | 209/18723 | 3.71e-05 | 9.14e-04 | 43 |
GO:00525488 | Lung | IAC | regulation of endopeptidase activity | 75/2061 | 432/18723 | 4.18e-05 | 1.01e-03 | 75 |
GO:00609964 | Lung | IAC | dendritic spine development | 25/2061 | 99/18723 | 5.18e-05 | 1.18e-03 | 25 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513024 | Breast | IDC | Pathogenic Escherichia coli infection | 42/867 | 197/8465 | 2.66e-06 | 3.92e-05 | 2.94e-05 | 42 |
hsa0481014 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
hsa045109 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
hsa052118 | Breast | IDC | Renal cell carcinoma | 14/867 | 69/8465 | 9.16e-03 | 4.37e-02 | 3.27e-02 | 14 |
hsa0517014 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
hsa0513034 | Breast | IDC | Pathogenic Escherichia coli infection | 42/867 | 197/8465 | 2.66e-06 | 3.92e-05 | 2.94e-05 | 42 |
hsa0481015 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
hsa0451013 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
hsa0521113 | Breast | IDC | Renal cell carcinoma | 14/867 | 69/8465 | 9.16e-03 | 4.37e-02 | 3.27e-02 | 14 |
hsa0517015 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
hsa0513043 | Breast | DCIS | Pathogenic Escherichia coli infection | 42/846 | 197/8465 | 1.40e-06 | 2.15e-05 | 1.59e-05 | 42 |
hsa0517024 | Breast | DCIS | Human immunodeficiency virus 1 infection | 33/846 | 212/8465 | 6.49e-03 | 3.22e-02 | 2.37e-02 | 33 |
hsa0481023 | Breast | DCIS | Regulation of actin cytoskeleton | 35/846 | 229/8465 | 6.89e-03 | 3.37e-02 | 2.48e-02 | 35 |
hsa0521123 | Breast | DCIS | Renal cell carcinoma | 14/846 | 69/8465 | 7.42e-03 | 3.48e-02 | 2.56e-02 | 14 |
hsa0513053 | Breast | DCIS | Pathogenic Escherichia coli infection | 42/846 | 197/8465 | 1.40e-06 | 2.15e-05 | 1.59e-05 | 42 |
hsa0517034 | Breast | DCIS | Human immunodeficiency virus 1 infection | 33/846 | 212/8465 | 6.49e-03 | 3.22e-02 | 2.37e-02 | 33 |
hsa0481033 | Breast | DCIS | Regulation of actin cytoskeleton | 35/846 | 229/8465 | 6.89e-03 | 3.37e-02 | 2.48e-02 | 35 |
hsa0521133 | Breast | DCIS | Renal cell carcinoma | 14/846 | 69/8465 | 7.42e-03 | 3.48e-02 | 2.56e-02 | 14 |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAK2 | SNV | Missense_Mutation | | c.1312G>A | p.Glu438Lys | p.E438K | Q13177 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PAK2 | SNV | Missense_Mutation | | c.1336N>A | p.Glu446Lys | p.E446K | Q13177 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PAK2 | SNV | Missense_Mutation | | c.103N>G | p.His35Asp | p.H35D | Q13177 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PAK2 | SNV | Missense_Mutation | | c.419N>C | p.Leu140Pro | p.L140P | Q13177 | protein_coding | tolerated(0.08) | possibly_damaging(0.62) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PAK2 | SNV | Missense_Mutation | novel | c.241G>A | p.Glu81Lys | p.E81K | Q13177 | protein_coding | tolerated(0.35) | possibly_damaging(0.734) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAK2 | SNV | Missense_Mutation | rs774110601 | c.1250N>A | p.Arg417Gln | p.R417Q | Q13177 | protein_coding | tolerated(0.11) | probably_damaging(0.993) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PAK2 | insertion | In_Frame_Ins | novel | c.627_628insTCTCGCTCTGTCGCC | p.Ser209_His210insSerArgSerValAla | p.S209_H210insSRSVA | Q13177 | protein_coding | | | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
PAK2 | insertion | Frame_Shift_Ins | novel | c.566_567insAAGAAGCAAACTTTTTGAAG | p.His189GlnfsTer17 | p.H189Qfs*17 | Q13177 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
PAK2 | insertion | Frame_Shift_Ins | novel | c.570_571insTTCATAAAGGGCGATAGTCG | p.Lys191PhefsTer15 | p.K191Ffs*15 | Q13177 | protein_coding | | | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
PAK2 | insertion | Nonsense_Mutation | novel | c.746_747insATGATACACAGTCATTGCTAACAACTAGTACAGTT | p.Tyr249Ter | p.Y249* | Q13177 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264720 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 249565812 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264719 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 329968394 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | allosteric modulator | 310264717 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264722 | | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 310264718 | PF-03758309 | |
5062 | PAK2 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 135652717 | STAUROSPORINE | |